Overview

Organ Transplant Immunosuppressant Drugs Market is poised to register a CAGR of 3.3% during the forecast period 2022 to 2028

FutureWise Market Research has illustrated a report on the Organ Transplant Immunosuppressant Drugs Market. The report provides an in-depth anatomy of the market trends affecting its growth. Moreover, it includes intricate insights on profitability graph, market share, SWOT analysis and geographical augmentation of this business. Furthermore, the report provides information on the status of key market players in the competitive landscape analysis of the market.
The Organ Transplant Immunosuppressant Drugs Market is projected to achieve significant growth by the end of the forecast period as per the research study conducted by FutureWise research analysts. The report explains that this business is predicted to record a remarkable growth rate over the forecast period. This report provides important information regarding the total valuation that this industry holds presently and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Organ Transplant Immunosuppressant Drugs Market are:   

• Astellas Pharma, Inc.
• Sanofi Genzyme
• Accord Healthcare Ltd.
• Novartis AG
• Mylan Laboratories , Inc.
• Dr. Reddy’s Laboratories Ltd.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Veloxis Pharmaceuticals A/S
• Bristol-Myers Squibb Company
(Note: The list of the major players will be updated with the latest market scenario and trends)

Organ Transplant Immunosuppressant Drugs Market Segmentation:

By Drug Class 

• Calcineurin Inhibitors
• Antiproliferative Agents
• mTOR Inhibitor
• Steroids
• Antibodies

By Transplant Type 

• Kidney
• Liver
• Heart
• Lung
• Pancreas
• Other

By Distribution Channel 

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia-Pacific
• Rest of the world

Competitive Landscape:

• Tier 1 players- established companies in the market with a major market share  
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Organ Transplant Immunosuppressant Drugs Market by drug class, by transplant type, by distribution channel and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific and rest of the world
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization services offered are free of charge with purchase of any license of the report.
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Organ Transplant Immunosuppressant Drugs Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Organ Transplant Immunosuppressant Drugs Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Organ Transplant Immunosuppressant Drugs Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Organ Transplant Immunosuppressant Drugs Market, By Drug Class Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Antibodies
   7.2. Steroids
   7.3. mTOR Inhibitor
   7.4. Antiproliferative Agents
   7.5. Calcineurin Inhibitors

8. Organ Transplant Immunosuppressant Drugs Market, By Transplant Type Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Kidney
   8.2. Liver
   8.3. Heart
   8.4. Lung
   8.5. Pancreas
   8.6. Other

9. Organ Transplant Immunosuppressant Drugs Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Hospital Pharmacies
   9.2. Retail Pharmacies
   9.3. Online Pharmacies

10. North America Organ Transplant Immunosuppressant Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. U.S.A
          10.2.2. Canada
          10.2.3. Mexico
    10.3. Market Size (USD Million) Forecast for North America 2022-2028

11. Latin America Organ Transplant Immunosuppressant Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Brazil
          11.2.2. Venezuela
          11.2.3. Argentina
          11.2.4. Rest of Latin America
    11.3. Market Size (USD Million) Forecast for Latin America 2022-2028

12. Europe Organ Transplant Immunosuppressant Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Germany
          12.2.2. U.K         
          12.2.3. France
          12.2.4. Italy
          12.2.5. Spain
          12.2.6. Russia
          12.2.7. Poland
          12.2.8. Rest of Europe
    12.3. Market Size (USD Million) Forecast for Europe 2022-2028

13. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Japan
          13.2.2. China
          13.2.3. India
          13.2.4. Australia and New Zealand
          13.2.5. ASEAN
          13.2.6. Rest of Asia Pacific
    13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. GCC
          14.2.2. Israel
          14.2.3. South Africa
          14.2.4. Rest of MEA
    14.3. Market Size (USD Million) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4. North America - Market Share Analysis and Key Regional Players
    15.5. Europe - Market Share Analysis and Key Regional Players
    15.6. Asia Pacific - Market Share Analysis and Key Regional Players
    15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    16.1. Astellas Pharma, Inc.
          16.1.1. Company Overview
          16.1.2. Product Portfolio
          16.1.3. SWOT Analysis
          16.1.4. Financial Overview
          16.1.5. Strategic Overview
    16.2. Sanofi Genzyme
          16.2.1. Company Overview
          16.2.2. Product Portfolio
          16.2.3. SWOT Analysis
          16.2.4. Financial Overview
          16.2.5. Strategic Overview 
    16.3. Accord Healthcare Ltd.
          16.3.1. Company Overview
          16.3.2. Product Portfolio
          16.3.3. SWOT Analysis
          16.3.4. Financial Overview
          16.3.5. Strategic Overview
    16.4. Novartis AG
          16.4.1. Company Overview
          16.4.2. Product Portfolio
          16.4.3. SWOT Analysis
          16.4.4. Financial Overview
          16.4.5. Strategic Overview
    16.5. Mylan Laboratories , Inc.
          16.5.1. Company Overview
          16.5.2. Product Portfolio
          16.5.3. SWOT Analysis
          16.5.4. Financial Overview
          16.5.5. Strategic Overview          
    16.6. Dr. Reddy’s Laboratories Ltd.
          16.6.1. Company Overview
          16.6.2. Product Portfolio
          16.6.3. SWOT Analysis
          16.6.4. Financial Overview
          16.6.5. Strategic Overview     
    16.7. F. Hoffmann-La Roche Ltd.
          16.7.1. Company Overview
          16.7.2. Product Portfolio
          16.7.3. SWOT Analysis
          16.7.4. Financial Overview
          16.7.5. Strategic Overview
    16.8. GlaxoSmithKline plc
          16.8.1. Company Overview
          16.8.2. Product Portfolio
          16.8.3. SWOT Analysis
          16.8.4. Financial Overview
          16.8.5. Strategic Overview 
    16.9. Veloxis Pharmaceuticals A/S
          16.9.1. Company Overview
          16.9.2. Product Portfolio
          16.9.3. SWOT Analysis
          16.9.4. Financial Overview
          16.9.5. Strategic Overview
    16.10.Bristol-Myers Squibb Company
          16.10.1. Company Overview
          16.10.2. Product Portfolio
          16.10.3. SWOT Analysis
          16.10.4. Financial Overview
          16.10.5. Strategic Overview
 
17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the regulations initiated by healthcare administrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client
 

Tables

Figures